HHAEMONETICS CORP logo
HAE//CIK 0000313143

HAEMONETICS CORP

Exchange

NYSE

Entity type

operating

Fiscal year end

Mar 28

Headquarters

MA

Research Summary

AI-assisted · Grounded in filings

Updated Nov 24, 2025

HAEMONETICS CORP

HAEMONETICS CORPORATION, which operates in SIC 3841 territory within the Surgical & Medical Instruments & Apparatus industry, is a global blood-management solutions company that combines automated apheresis systems, disposables, and analytics software to help hospitals, blood centers, and cell therapy innovators optimize blood collection, processing and transfusion therapy. Its offerings include cell salvage, pathogen-inactivation disposables, and integrated monitoring platforms that align with clinical teams focused on surgical suites, transplant programs, and trauma centers, while the services side supports training, field installation and remote monitoring to keep facilities compliant. The company continually invests in regulatory quality because the FDA, EMA and other agencies oversee device approvals, post-market surveillance, and manufacturing controls, so supply-chain disruptions, reimbursement pressures, and evolving device standards are material risks that could affect revenue visibility. CIK 313143 filed a Form 10-Q in November 1999, which remains the latest public periodic report, and investors tracking HAE should view live SEC filings on Earnings Feed.

Market Data

Dec 3, 12:16 PM ET
$81.72+$31.45 (+62.56%)

HAE · Last trade

Prev Close

$50.27

Range (30d)

$50.27 – $81.72

$40.00$60.00$80.00$100.00Nov 3Nov 12Nov 21Dec 3